
Thor Halfdanarson/mayoclinic.org
Jun 5, 2025, 08:31
Thor Halfdanarson: PRRT in NETs – Efficacy and Risk of Treatment-Related Myeloid Neoplasms
Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X:
“PRRT is a very effective for well-differentiated NETs but associated with a low risk of treatment related myeloid neoplasms ( t-MN ). If you are interested in learning more, this is the review for you.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 07:54
Jun 5, 2025, 05:59
Jun 5, 2025, 05:45